Information  X 
Enter a valid email address

Tekcapital plc (TEK)


Thursday 14 October, 2021

Tekcapital plc

Salarius FDA Sodium Reduction Goals

RNS Number : 0069P
Tekcapital plc
14 October 2021


14 October 2021

Tekcapital Plc

("Tekcapital", the "Company" or "the Group")


Portfolio Company Update: Salarius, Ltd. ("Salarius")

FDA Releases Voluntary Sodium Reduction Goals for the Food Industry


Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF) the UK intellectual property investment group focused on creating valuable products from investing in university technology that can improve people's lives, is very pleased to announce that the U.S. Food and Drug Administration (FDA) has just released voluntary sodium reduction goals for the food industry "to provide measurable voluntary short-term (2.5-year) goals for sodium content in commercially processed, packaged, and prepared foods to reduce excess population sodium intake." [i]


Dr. Jennifer Ashton,  ABC News chief medical correspondent said "the news from acting FDA Commissioner Janet Woodcock and Susan T. Mayne, director of the FDA's Center for Food Safety and Applied Nutrition, could be the biggest, most important intervention in a generation for public health."[ii]


This is a significant milestone for Salarius for the following reasons:


· We believe the FDA guidelines will encourage snack food manufactures to reduce the sodium levels in their products across the board;

· Salarius anticipates this should have a positive impact on both B2B sales of MicroSalt® and retail sales of SaltMe! crisps;

· MicroSalt® as a brand could be viewed as a timely, nationwide solution, to help food companies meet these guidelines without sacrificing the full-flavour of their snack foods, which is key to their successful on-going sales.


MicroSalt aims to revolutionize the food industry with its patented sodium microparticle, that delivers the full-flavour experience of salt with roughly half the sodium. MicroSalt's salt particles are approximately 100 times smaller than regular table salt, allowing them to rapidly dissolve, producing a large sensation of saltiness. MicroSalt® is all-natural, non-GMO, and Kosher.


"We're very excited to see the FDA take a leadership role in encouraging the food industry to embark on meaningful sodium reduction programs for their products," said Victor Hugo Manzanilla, CEO of MicroSalt. "This is a major milestone for the country, and we are ready to partner with food manufacturers to help them comply with the new guidelines whilst maintaining the full-flavour of their snacks."


About Salarius Ltd.

Salarius, is the developer and manufacturer of a proprietary low-sodium salt called MicroSalt®. We are passionate about improving peoples' lives with better-for-you snacks by taking the lead in the industry by providing the best low-sodium salt solution, based on the mechanical transformation of the salt particle itself. This solution is the only one that delivers real salt flavor because it is salt. Our new patented technology produces salt crystals that are approximately one hundred times smaller than typical table salt, delivering a powerful saltiness as the micro-grains dissolve in the mouth, with approximately 50% less sodium consumption. Additionally, the ultra-small particle size enhances product adhesion, which reduces waste and provides improved flavor consistency. MicroSalt® and SaltMe® are registered trademarks of MicroSalt Inc.


To learn more about MicroSalt please visit .  

To learn more about SaltMe! snacks please visit .


Tekcapital owns 97.2% of the share capital of Salarius Ltd. and 87.1% of the share capital of MicroSalt Inc., its U.S. subsidiary.


About Tekcapital plc

Tekcapital creates value from investing in new, university-developed discoveries that can enhance people's lives and provides a range of technology transfer services to help organisations evaluate and commercialise new technologies. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in the UK. For more information, please visit .


For further information, please contact:

Tekcapital Plc  


Via Flagstaff IR

Clifford M. Gross, Ph.D. 






SP Angel  Corporate Finance LLP  (Nominated Adviser and Broker)


+44 (0) 20 3470 0470  

Richard Morrison / Charlie Bouverat (Corporate Finance)

Rob Rees (Corporate Broking)





Flagstaff Strategic and Investor Communications     +44 (0)207 129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon 


This press release is for informational purposes only. The information herein does not constitute investment advice nor an offer to invest and may contain statements related to our future business and financial performance and future events or developments involving Salarius that may constitute forward-looking statements. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to customers, stakeholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements may be based on the current expectations and certain assumptions of Salarius' and/or Tekcapital's management. Please note that these are subject to a number of risks, uncertainties and factors, including, but not limited to those described in various disclosures. Should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Salarius or Tekcapital may vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Neither Salarius nor Tekcapital intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.




This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t